BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18455928)

  • 1. Carcinogenesis in Down syndrome: what can be learned from trisomy 21?
    Satgé D; Bénard J
    Semin Cancer Biol; 2008 Oct; 18(5):365-71. PubMed ID: 18455928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
    Satgé D
    Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21.
    Stepensky P; Brooks R; Waldman E; Revel-Vilk S; Izraeli S; Resnick I; Weintraub M
    Pediatr Blood Cancer; 2010 Jul; 54(7):1048-9. PubMed ID: 20108342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA1 mutations in acute leukemia in children with Down syndrome.
    Magalhães IQ; Splendore A; Emerenciano M; Figueiredo A; Ferrari I; Pombo-de-Oliveira MS
    Cancer Genet Cytogenet; 2006 Apr; 166(2):112-6. PubMed ID: 16631466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J; Zipursky A
    Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 14. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
    Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
    Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomy of chromosome 21 in leukemogenesis.
    Izraeli S; Rainis L; Hertzberg L; Smooha G; Birger Y
    Blood Cells Mol Dis; 2007; 39(2):156-9. PubMed ID: 17532652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of GATA1 mutation in acute megakaryocytic leukemia].
    Ito E
    Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
    [No Abstract]   [Full Text] [Related]  

  • 17. GATA1 mutations in myeloproliferative disorders: nomenclature standardization and review of the literature.
    Splendore A; Magalhães IQ; Pombo-de-Oliveira MS
    Hum Mutat; 2005 Oct; 26(4):390-2. PubMed ID: 16134163
    [No Abstract]   [Full Text] [Related]  

  • 18. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
    Vyas P; Roberts I
    Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A leukemogenic twist for GATA1.
    Look AT
    Nat Genet; 2002 Sep; 32(1):83-4. PubMed ID: 12172549
    [No Abstract]   [Full Text] [Related]  

  • 20. Information dynamics in carcinogenesis and tumor growth.
    Gatenby RA; Frieden BR
    Mutat Res; 2004 Dec; 568(2):259-73. PubMed ID: 15542113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.